trial · primary record
Bimekizumab
Hidradenitis Suppurativa
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 509 |
| Primary completion | 2022-09-28 |
| Primary endpoint | Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 |
| Registry ID | NCT04242498 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:10.732Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04242498
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.